ArticleNo Access
METHOXYPROMAZINE IN CHRONIC SCHIZOPHRENIA
Published Online:1 Apr 2006https://doi.org/10.1176/ajp.117.1.72
Abstract
No appreciable change in adjustment was noted in 12 chronically ill schizophrenics who were subjects of a 6-month double blind study with methoxypromazine. No toxic or untoward side effects were noted with doses ranging from 100 to 600 mg. daily.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
